Detailed Narrative
Q2 FY26 Performance Overview and Strategic Shift
Glenmark Pharmaceuticals reported a robust 76% YoY consolidated revenue growth to INR 60,469 million in Q2 FY26, with H1 FY26 revenue reaching INR 93,113 million, up 39.4% YoY. This growth was significantly bolstered by the North America business, which recorded sales of INR 44,656 million, though its core business growth, excluding the ISB 2001 out-licensing income, was 7.4%. Europe operations also contributed positively with an 8.5% growth to INR 7,460 million. The company announced a strategic shift into 'Glenmark 3.0,' aiming for sustainable growth, a strong balance sheet, and prudent capital allocation, driven by the recent ISB 2001 deal.
India Business Disruption and Recovery Outlook
The India formulation business experienced a sharp 87% YoY decline in Q2 FY26, with sales falling to INR 1,650 million. This significant drop was primarily attributed to a one-time📎 reduction in distributor inventory, order postponements, and logistics issues following the GST regime change on August 15, compounded by Glenmark's unique 3-tier distribution model. Despite this, the India formulation business showed secondary sales growth of 10.8% in Q2 and 11.4% MAT September. Management expects a strong recovery, projecting a run rate of INR 1,150-1,200 crores from Q3 FY26 and a top line exceeding INR 4,800 crores in FY27.
Capital Structure and Debt Reduction
The $700 million upfront payment from the ISB 2001 deal significantly transformed Glenmark's financial position. The company utilized these proceeds to repay INR 1,300 crores of gross debt and is now net cash positive with INR 2,647 crores in hand. Management committed to achieving zero gross debt by the end of FY26. Additionally, the company has revised its provisioning norms and standard operating procedures, which, while leading to one-time📎 charges, are expected to improve overall return ratios and ensure true capital efficiencies.
Innovation Pipeline and IGI's Strategic Importance
Glenmark emphasized its continued investment in its innovative R&D platform, particularly through IGI (Glenmark Life Sciences), which is seen as a key growth driver. The ISB 2001 deal, with potential milestones up to $1.225 billion, validated this strategy. IGI plans to spend $70-75 million annually to advance its pipeline, with the first multi-specific NK cell engager, ISB 2301, entering clinics in FY27. The company aims to close new partnerships for its innovative assets within the next five years, leveraging its unique multi-specific antibody platform.
Global Specialty Product Traction and Expansion
Glenmark's specialty portfolio, including RYALTRIS, WINLEVI, TEVIMBRA, BRUKINSA, LIRAFIT, and JABRYUS, continues to gain global traction. RYALTRIS, already commercialized in 49 markets, received approval in China via Grand Pharma, with a launch planned for H1 next fiscal year, and is set for launch in Thailand in Q4. WINLEVI has launched in the UK with positive initial response and is awaiting approval in other European markets, contributing to the double-digit growth expected in Europe in H2 FY26. The company also plans to file 2 ANDAs in the upcoming quarter and launch 3-4 products each quarter in the US.
One-Time Expenses and Working Capital Adjustments
The company incurred INR 650 crores in one-time📎 expenses, including R&D team incentives, legal/consulting fees related to the ISB 2001 deal, and costs for facility closures in Switzerland. An additional INR 200 crores was expensed for a previously provisioned legal settlement. The discontinuation of legacy pre-collection arrangements with distributors led to an increase in debtors by approximately INR 800 crores and an overall working capital change of INR 1,600 crores. These adjustments are expected to support improved operating margins and a net working capital cycle of 110-115 days going forward⏳.